A September 2nd update from the FDA cites manufacturing delays at Bedford Laboratories and Teva Pharmaceuticals for leucovorin shortages.
Here at the Colorectal Cancer Coalition, we’re hearing from patients who are not receiving leucovorin during their chemotherapy because it just isn’t available.
Bedford says that they will be releasing some 350 mg and 200 mg vials in September and are working on other presentations. Teva is allocating 100 mg vials and says that the 350 mg vials are on back-order with an expected release date in the fourth quarter of 2010.
Spectrum Pharmaceuticals has supplies of Fusilev® (levoleucovorin). However, the FDA warns that there is a possibility for dosing errors in substituting Fusilev for leucovorin:
Reminder: There is potential for dosing errors when interchanging leucovorin and levoleucovorin (Fusilev). The dose of levoleucovorin (Fusilev) is one-half the dose of racemic leucovorin injection (e.g., levoleucovorin [Fusilev] 7.5 mg = racemic leucovorin 15 mg)
More information on the leucovorin shortage is available from the American Society of Health-System Pharmacists (ASHP).